Regeneron Pharmaceuticals (NASDAQ:REGN) Given a $635.00 Price Target by Evercore ISI Analysts

Evercore ISI set a $635.00 price objective on Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) in a research report released on Monday, Stock Target Advisor reports.

A number of other research analysts have also weighed in on REGN. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $620.00 to $610.00 and set an equal weight rating on the stock in a research note on Friday, June 3rd. SVB Leerink assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Monday, May 23rd. They issued an outperform rating and a $738.00 price target on the stock. Barclays lifted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an overweight rating in a research note on Tuesday, April 12th. Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $640.00 to $645.00 in a research note on Wednesday, April 20th. Finally, Jefferies Financial Group lowered shares of Regeneron Pharmaceuticals to a sell rating and set a $536.00 price target on the stock. in a research note on Friday, June 17th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average target price of $707.43.

Regeneron Pharmaceuticals stock opened at $607.39 on Monday. The company’s 50 day simple moving average is $643.06 and its 200 day simple moving average is $642.97. Regeneron Pharmaceuticals has a fifty-two week low of $531.33 and a fifty-two week high of $747.42. The firm has a market capitalization of $65.93 billion, a price-to-earnings ratio of 8.60, a PEG ratio of 1.81 and a beta of 0.25. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.76 and a quick ratio of 4.09.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share for the quarter, topping the consensus estimate of $9.37 by $2.12. Regeneron Pharmaceuticals had a net margin of 48.06% and a return on equity of 50.10%. The business had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the firm earned $10.09 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 17.2% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals will post 40.63 EPS for the current fiscal year.

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $650.78, for a total transaction of $65,078.00. Following the transaction, the director now directly owns 22,182 shares in the company, valued at $14,435,601.96. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $701.82, for a total transaction of $701,820.00. Following the transaction, the executive vice president now owns 22,014 shares in the company, valued at $15,449,865.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 21,595 shares of company stock worth $15,319,478. 11.84% of the stock is owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the business. Glassman Wealth Services increased its holdings in shares of Regeneron Pharmaceuticals by 19.5% in the first quarter. Glassman Wealth Services now owns 92 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 15 shares during the last quarter. Minot Wealth Management LLC grew its stake in shares of Regeneron Pharmaceuticals by 3.8% in the first quarter. Minot Wealth Management LLC now owns 408 shares of the biopharmaceutical company’s stock valued at $285,000 after acquiring an additional 15 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Regeneron Pharmaceuticals by 9.9% in the first quarter. EverSource Wealth Advisors LLC now owns 167 shares of the biopharmaceutical company’s stock valued at $117,000 after acquiring an additional 15 shares in the last quarter. Stratos Wealth Partners LTD. grew its stake in shares of Regeneron Pharmaceuticals by 3.1% in the first quarter. Stratos Wealth Partners LTD. now owns 535 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 16 shares in the last quarter. Finally, Pinnacle Wealth Planning Services Inc. grew its stake in shares of Regeneron Pharmaceuticals by 4.1% in the fourth quarter. Pinnacle Wealth Planning Services Inc. now owns 429 shares of the biopharmaceutical company’s stock valued at $271,000 after acquiring an additional 17 shares in the last quarter. Hedge funds and other institutional investors own 83.83% of the company’s stock.

About Regeneron Pharmaceuticals (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.